Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

The following is a summary of "Mediastinal staging lymph node probability map in non-small cell lung cancer,” published in the March 2025 issue of Respiratory Research by Bordas-Martinez et al.

Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...

Dame Esther Rantzen’s daughter has revealed that the ‘amazing’ new drug that was delaying the spread of her mother’s cancer ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...